RE:RE:RE:RE:AACR - late breaking absracts text posted by noon todayI had few email interactions with Elif firstly she was very helpful and responsive. I suggested more details about the rationale behind the restart and amended protocol to be shared with investors she passed the message to the CMO and he apparently didn't think they are ready to discuss the details but when they are they will. So we might get that "explanation" in the future. My understanding is the management call the shots so critizing the IR lady calling her names is not appropriate at all as she gets her orders from management.
qwerty22 wrote: The internalization observation with the fluorescence is not something new, they've presented that before. Maybe it's specific localization is new, I don't remember knowing that detail but I might be wrong.
I'd say the development time on much of this work, especially the immunotherapy angle is likely much more than 3-4 months so all this is work that likely started well before they were hit with the pause.
We are back to the same position as before. Preclinical look super promising but it didn't stay that way in the clinic. It's squaring that circle that needs to be addressed. The immunotherapy angle is certainly a new possible path, more complex (and expensive) if they are considering a combo trial but another well worn path by other biotech. If I was them I'd still be nagged by the lack of success in their first go at this. It really needs an explanation still.
Wino115 wrote: There's 3 presentatins - one is the ongoing human sort1 tissue staining samples to build the database up (useful for future patient selection), one on TNBC (which you have here) - this is why they confidently state internalization is quick as they now have flourescent readings and see that the peptide is actually getting inside the tumor cell as opposed to Herceptin which hangs around the neighborhood on the surface only. Once again --mice, not humans unfortunately. This is the UMAQ sponsored stuff. Good data, but similar to what we've seen on other mice tumors.
The wildcared one is the Immunotherapy combo data most likely. I noticed that the conference website says there will be no e-posters available for this conference so we have to rely on THTX to post the actual posters once they've presented them. I may have read it wrong, but the AACR website doesn't seem to have any posters, just the abstracts with limited data on them.